What is Roche Holding AG's (ROP.SW) StockRank?

MoatMap's StockRank for Roche Holding AG (ROP.SW) is 97/100, with a Strong Buy signal. This is a composite score combining Quality (77), Value (51), and Momentum (73) factor ranks across MoatMap's 20,000+ stock universe.

Does Roche Holding AG have an economic moat?

Roche Holding AG (ROP.SW) has a Quality factor score of 77/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Roche Holding AG a buy, hold, or sell?

MoatMap's current signal for Roche Holding AG (ROP.SW) is Strong Buy, based on a StockRank of 97/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Roche Holding AG in?

Roche Holding AG (ROP.SW) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry (Switzerland).

Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

ROP.SW

STRONG BUY

Roche Holding AG · Healthcare · Switzerland · $323.7B · Avg Vol: $469M/d

StockRank

Get insider-trade alerts

P/E (TTM)

21.1x

ROE

37.3%

D/E

0.9x

Dividend %

2.9%

COMPANY DESCRIPTION

Roche Holding AG is a global healthcare giant operating in two primary divisions: Pharmaceuticals and Diagnostics. The company is a world leader in oncology treatments, personalized medicine, and in-vitro diagnostics, supported by an industry-leading research and development budget. Roche's competitive moat is sustained by its extensive patent portfolio, high switching costs in diagnostic platforms, and a robust pipeline of novel biologic therapies.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	81.3B	74.7B	77.1B	78.3B	-1.3%	78.3B	79.6B	82.9B	2.9%
EPS	19.17	17.79	12.83	19.99	1.4%	19.81	20.70	22.28	5.6%
Shares	809.3M	809.3M	809.3M	809.3M	0.0%	688.9M	—	—	—
Debt	32.8B	38.0B	44.9B	41.0B	7.7%	41.0B	—	—	—
Equity	34.6B	36.2B	39.2B	41.8B	6.5%	—	—	—	—
Op CF	22.0B	19.9B	24.8B	23.3B	1.9%	23.3B	—	—	—
Inv CF	-3.6B	-13.1B	-14.1B	-10.6B	—	—	—	—	—
Fin CF	-20.1B	-5.2B	-8.4B	-14.0B	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+6.7%

SMA 50SMA 200

$418.52

RSI (14)

64.7

52W High

$449.37

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

25.2%95.0

ROE

37.3%95.4

GP/Assets

46.9%85.5

Op. Margin

30.0%91.5

FCF/Assets

13.0%91.4

Piotroski

782.9

Int. Cover

13.6x64.2

D/E Ratio

0.88x18.2

Current Ratio

1.38x22.4

Value

P/E (TTM)

21.1x54.9

EV/EBITDA

12.0x58.7

P/FCF

20.0x59.2

P/B

8.0x15.9

P/S

4.3x46.6

Div Yield

2.9%66.3

Momentum

52W High %

93%86.6

RS 6M

-4%66.7

SMA 50/200

1.04x74.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+35%45.1

Q Growth

171%90.9

FUNDAMENTALS

Market Cap

$323.7B

P/E (Forward)

15.6x

Gross Margin

74.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ROP.SW are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ROP.SW	Roche Holding AG(you)	$323.7B	97	STRONG BUY
MRK.MX	Merck & Co., Inc.	$316.3B	98	STRONG BUY
AMGN.MX	Amgen Inc.	$192.8B	96	STRONG BUY
NOVN.SW	Novartis AG	$297.7B	85	STRONG BUY
ABBV	AbbVie Inc.	$364.6B	85	STRONG BUY
NVON.MX	Novo Nordisk A/S	$212.5B	90	STRONG BUY
GIS.DE	Gilead Sciences, Inc.	$157.4B	97	STRONG BUY
JNJ.MX	Johnson & Johnson	$588.5B	93	STRONG BUY
AZN	AstraZeneca PLC	$292.2B	83	STRONG BUY
PFE.MX	Pfizer Inc.	$137.8B	95	STRONG BUY

Peer medians: ROE 2.7% · P/E 22.9x · Gross margin 47.5%

Price	$418.52
Market Cap	$323.7B
P/E (TTM)	21.10
P/E (Forward)	15.59
Price/Book	7.97
Return on Equity	37.3%
Return on Invested Capital	25.2%
Debt/Equity	87.64
Gross Margin	74.5%
Operating Margin	30.0%
Revenue Growth	-0.4%
Dividend Yield	2.9%
Free Cash Flow	$16.1B